Supernus Pharmaceuticals, Inc.
SUPN
$32.15
$0.451.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -13.97% | -0.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.97% | -0.87% | |||
| Cost of Revenue | -39.60% | 48.43% | |||
| Gross Profit | -9.46% | -6.35% | |||
| SG&A Expenses | 15.60% | 0.44% | |||
| Depreciation & Amortization | 8.45% | -6.38% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.44% | 4.91% | |||
| Operating Income | -135.77% | -30.95% | |||
| Income Before Tax | -122.10% | -41.30% | |||
| Income Tax Expenses | -45.76% | 71.49% | |||
| Earnings from Continuing Operations | -177.16% | -60.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -177.16% | -60.18% | |||
| EBIT | -135.77% | -30.95% | |||
| EBITDA | -65.14% | -20.70% | |||
| EPS Basic | -176.59% | -60.40% | |||
| Normalized Basic EPS | -110.42% | -24.79% | |||
| EPS Diluted | -178.20% | -60.77% | |||
| Normalized Diluted EPS | -110.61% | -24.96% | |||
| Average Basic Shares Outstanding | 0.72% | 0.57% | |||
| Average Diluted Shares Outstanding | -1.06% | 0.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||